BIOMAT Database Logo BIOMAT Database Logo

Reversible inhibition of phagocytosis in anephric uremic patients. 1973

R L Burleson

UI MeSH Term Description Entries
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D009392 Nephrectomy Excision of kidney. Heminephrectomy,Heminephrectomies,Nephrectomies
D010586 Phagocytes Cells that can carry out the process of PHAGOCYTOSIS. Phagocyte,Phagocytic Cell,Phagocytic Cells,Cell, Phagocytic,Cells, Phagocytic
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001002 Anuria Absence of urine formation. It is usually associated with complete bilateral ureteral (URETER) obstruction, complete lower urinary tract obstruction, or unilateral ureteral obstruction when a solitary kidney is present. Anurias
D014511 Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms. Uremias

Related Publications

R L Burleson
Erythropoietin levels in uremic nephric and anephric patients.
March 1979, The Journal of laboratory and clinical medicine,
R L Burleson
Phagocytosis in Tetrahymena thermophila: naloxone-reversible inhibition by opiates.
January 1989, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology,
R L Burleson
Phagocytosis in uremic mice.
November 1972, Journal of the Reticuloendothelial Society,
R L Burleson
Erythrocyte production and metabolism in anephric and uremic men.
March 1968, Annals of the New York Academy of Sciences,
R L Burleson
Reversible uremic states.
June 1956, Journal of the American Medical Association,
R L Burleson
Renin and renin inhibition in anephric man.
March 1993, Clinical and experimental hypertension (New York, N.Y. : 1993),
R L Burleson
[Erythropoiesis in anephric patients].
December 1971, Schweizerische medizinische Wochenschrift,
R L Burleson
Naloxone-reversible inhibition by opiates of phagocytosis in Tetrahymena thermophila and mouse macrophages.
August 1988, Puerto Rico health sciences journal,
R L Burleson
Effect of verapamil on disposition of intravenous potassium in diabetic anephric uremic rats.
January 1993, Mineral and electrolyte metabolism,
R L Burleson
Generation of superoxide anions during phagocytosis by monocytes of uremic patients.
January 1984, Nephron,
Copied contents to your clipboard!